Literature DB >> 11926210

High prevalence of undetected ulcerative colitis: data from the Nottingham fecal occult blood screening trial.

G F Howarth1, M H E Robinson, D Jenkins, J D Hardcastle, R F A Logan.   

Abstract

OBJECTIVES: Inflammatory bowel disease (IBD) is usually diagnosed as a result of symptoms but occasionally is found during investigation for other conditions. An earlier report from Nottingham had found a high prevalence of previously undetected "asymptomatic" IBD detected as a result of colorectal cancer screening, and the aim of this study was to reassess the prevalence, symptoms, and outcome in these patients.
METHODS: We investigated subjects found to be fecal occult blood (FOB) positive in a randomized trial of FOB screening for colorectal cancer. All FOB-positive subjects were investigated by colonoscopy or flexible sigmoidoscopy and barium enema. Subjects with IBD were referred back to their general practitioner for any further investigation and treatment.
RESULTS: Seventy-five thousand two hundred fifty-three subjects (aged 45-74) were sent FOB tests and 44,838 (60%) completed a series of tests on one or more occasions. Of 133,000 test series, 1.5% were positive. During investigation 53 cases of previously undetected IBD (52 of ulcerative colitis) were found; 52% (27/52) had proctosigmoiditis only, whereas 25% (13/52) had pancolitis. Only 17% (9/52) were completely asymptomatic, with a half or more reporting some rectal bleeding (54%) or diarrhea (50%). The overall prevalence of undetected ulcerative colitis was 69/10(5) (95% CI = 50-88/10(5)) in people offered screening and 116/10(5) (95% CI = 85-147/10(5)) in people accepting screening and was higher in men. Of 32 subjects followed up 2-12 yr after diagnosis, 91% (29) continued to have few or no symptoms, with only 12 currently receiving any treatment for their colitis.
CONCLUSIONS: In comparison with detected disease, undetected ulcerative colitis is relatively common but does usually cause some symptoms. It generally appears to follow a benign course, but a significant proportion have extensive colitis and may therefore be at an increased risk of colorectal cancer.

Entities:  

Mesh:

Year:  2002        PMID: 11926210     DOI: 10.1111/j.1572-0241.2002.05586.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

1.  Incidence and prevalence of ulcerative colitis in Punjab, North India.

Authors:  A Sood; V Midha; N Sood; A S Bhatia; G Avasthi
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

2.  Peripartum Antibiotics Promote Gut Dysbiosis, Loss of Immune Tolerance, and Inflammatory Bowel Disease in Genetically Prone Offspring.

Authors:  Jun Miyoshi; Alexandria M Bobe; Sawako Miyoshi; Yong Huang; Nathaniel Hubert; Tom O Delmont; A Murat Eren; Vanessa Leone; Eugene B Chang
Journal:  Cell Rep       Date:  2017-07-11       Impact factor: 9.423

3.  Increasing rates and changing patterns of hospital admissions for patients with inflammatory bowel disease in Ireland: 1996-2001.

Authors:  C M Smyth; S Bacheer Picha; O Rathore; J Deasy; S E Patchett; F E Murray
Journal:  Ir J Med Sci       Date:  2005 Oct-Dec       Impact factor: 1.568

4.  Endoscopic features and clinical course of patients with asymptomatic cecal ulcers.

Authors:  Fang-We Chiu; Chung-Wang Ko; Ying-Cheng Lin; Szu-Chia Liao; Chung-Hsin Chang; Chia-Chang Chen; Wan-Tzu Lin
Journal:  BMC Gastroenterol       Date:  2022-06-24       Impact factor: 2.847

5.  Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.

Authors:  Marc Tänzer; Benjamin Balluff; Jürgen Distler; Kari Hale; Andreas Leodolter; Christoph Röcken; Bela Molnar; Roland Schmid; Catherine Lofton-Day; Tibor Schuster; Matthias P A Ebert
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

6.  Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases.

Authors:  Ichiro Hirata; Masahiro Hoshimoto; Osamu Saito; Masanobu Kayazawa; Takashi Nishikawa; Mitsuyuki Murano; Ken Toshina; Fang-Yu Wang; Ryoichi Matsuse
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

7.  Inflammatory bowel diseases and the general practitioner's role in a region of Central Italy.

Authors:  Paolo Sossai; Fabio Filippetti; Ali Ahmad Muselmani; Giambattista Catalini
Journal:  Clin Exp Gastroenterol       Date:  2010-04-20

8.  A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions.

Authors:  Haruka Hirono; Kazuhiko Watanabe; Katsuhiko Hasegawa; Terasu Honma; Yoichi Ajioka; Shogo Ohkoshi
Journal:  Am J Case Rep       Date:  2018-05-31

Review 9.  Silent Inflammatory Bowel Disease.

Authors:  Matthew D Coates; David G Binion
Journal:  Crohns Colitis 360       Date:  2021-09-22

Review 10.  Diagnosis and natural history of preclinical and early inflammatory bowel disease.

Authors:  Iago Rodríguez-Lago; Yamile Zabana; Manuel Barreiro-de Acosta
Journal:  Ann Gastroenterol       Date:  2020-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.